Literature DB >> 30632182

A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients.

Carolina Salcedo1, Pieter H Joubert1,2, Miguel D Ferrer1,3, Ana Z Canals1, Francisco Maduell4, Vicens Torregrosa4, Josep Maria Campistol4, Raquel Ojeda4, Joan Perelló1,5.   

Abstract

Entities:  

Keywords:  SNF472; cardiovascular calcification; haemodialysis; hydroxyapatite; myo-inositol hexaphosphate; renal disease

Mesh：

Substances：

Year:  2019        PMID： 30632182      PMCID： PMC6422667          DOI： 10.1111/bcp.13863

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  36 in total

1.  Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease.

Authors:  J Blacher; A P Guerin; B Pannier; S J Marchais; G M London
Journal:  Hypertension       Date:  2001-10       Impact factor: 10.190

2.  Phytate (myo-inositol hexaphosphate) and risk factors for osteoporosis.

Authors:  A A López-González; F Grases; P Roca; B Mari; M T Vicente-Herrero; A Costa-Bauzá
Journal:  J Med Food       Date:  2008-12       Impact factor: 2.786

Review 3.  Phytate (IP6) is a powerful agent for preventing calcifications in biological fluids: usefulness in renal lithiasis treatment.

Authors:  F Grases; A Costa-Bauzá
Journal:  Anticancer Res       Date:  1999 Sep-Oct       Impact factor: 2.480

4.  Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients.

Authors:  Ronney S Shantouf; Matthew J Budoff; Naser Ahmadi; Arshia Ghaffari; Ferdinand Flores; Ambarish Gopal; Nazanin Noori; Jennie Jing; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2010-04-09       Impact factor: 3.754

5.  Changes in QT interval before and after hemodialysis.

Authors:  Mohammad Reza Khosoosi Niaki; Mehrdad Saravi; Farshid Oliaee; Roghayeh Akbari; Sepideh Noorkhomami; Seyed Hassan Bozorgi Rad; Kobra Fallahpoor; Mir Saeed Ramezani
Journal:  Caspian J Intern Med       Date:  2013

Review 6.  Vascular calcification: When should we interfere in chronic kidney disease patients and how?

Authors:  Usama Abdel Azim Sharaf El Din; Mona Mansour Salem; Dina Ossama Abdulazim
Journal:  World J Nephrol       Date:  2016-09-06

Review 7.  Vascular calcification mechanisms.

Authors:  Cecilia M Giachelli
Journal:  J Am Soc Nephrol       Date:  2004-12       Impact factor: 10.121

8.  Metabolism of 14C-phytate in rats: effect of low and high dietary calcium intakes.

Authors:  A Nahapetian; V R Young
Journal:  J Nutr       Date:  1980-07       Impact factor: 4.798

9.  Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis.

Authors:  Vincenzo Savica; Domenico Santoro; Paolo Monardo; Agostino Mallamace; Guido Bellinghieri
Journal:  Ther Clin Risk Manag       Date:  2008-08       Impact factor: 2.423

10.  A novel pharmacodynamic assay to evaluate the effects of crystallization inhibitors on calcium phosphate crystallization in human plasma.

Authors:  M D Ferrer; M M Pérez; M M Cànaves; J M Buades; C Salcedo; J Perelló
Journal:  Sci Rep       Date:  2017-07-31       Impact factor: 4.379
View more
  6 in total

1.  Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis.

Authors:  Joan Perelló; Miquel D Ferrer; Maria Del Mar Pérez; Nadine Kaesler; Vincent M Brandenburg; Geert J Behets; Patrick C D'Haese; Rekha Garg; Bernat Isern; Alex Gold; Myles Wolf; Carolina Salcedo
Journal:  Br J Pharmacol       Date:  2020-08-23       Impact factor: 8.739

2.  A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients.

Authors:  Carolina Salcedo; Pieter H Joubert; Miguel D Ferrer; Ana Z Canals; Francisco Maduell; Vicens Torregrosa; Josep Maria Campistol; Raquel Ojeda; Joan Perelló
Journal:  Br J Clin Pharmacol       Date:  2019-02-19       Impact factor: 4.335

3.  A novel assay to measure calcification propensity: from laboratory to humans.

Authors:  M Mar Perez; Miguel D Ferrer; Marta Lazo-Rodriguez; Ana Zeralda Canals; Elisenda Banon-Maneus; Josep M Campistol; Stephan Miller; Rekha Garg; Alex Gold; Carolina Salcedo; Joan Perelló
Journal:  Sci Rep       Date:  2020-10-16       Impact factor: 4.379

4.  Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification.

Authors:  Antonio Bellasi; Paolo Raggi; Jordi Bover; David A Bushinsky; Glenn M Chertow; Markus Ketteler; Mariano Rodriguez; Smeeta Sinha; Carolina Salcedo; Rekha Garg; Alex Gold; Joan Perelló
Journal:  Clin Kidney J       Date:  2019-10-30

Review 5.  New Therapeutics Targeting Arterial Media Calcification: Friend or Foe for Bone Mineralization?

Authors:  Astrid Van den Branden; Anja Verhulst; Patrick C D'Haese; Britt Opdebeeck
Journal:  Metabolites       Date:  2022-04-05

Review 6.  Cardiovascular Calcification in Chronic Kidney Disease-Therapeutic Opportunities.

Authors:  Anika Himmelsbach; Carina Ciliox; Claudia Goettsch
Journal:  Toxins (Basel)       Date:  2020-03-14       Impact factor: 4.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.